Biologic dressings and negative pressure wound therapy are two of the newer types of wound care products in the infant stages of development, whereas more mature products include anti-infectives and pressure relief devices, notes a new report by healthcare market research publisher Kalorama Information.
“Besides the always-improving synthetic dressing materials, newer technologies in wound treatment include the xenogeneic tissue scaffold, bilayered human dermal substitutes, recombinant growth factors, endoscopic subfascial ligation of venous perforators and endovascular arterial repair techniques, says Mary Ann Crandall, analyst of the report, titled Advanced Wound Care Markets Worldwide. “New wound care products and devices are entering the market with lightening speed.”
Long-term expansion of wound care offerings is being driven by an aging population, longer life expectancies and an increasing number of sicker patients/residents across all care settings, according to Kalorama, which says that the worldwide wound care market reached revenues of almost $19 billion in 2013, growth of six percent over the previous year.
The top wound care companies worldwide—responsible for more than 50 percent of the revenues for the total market—include Johnson & Johnson, KCI, Covidien, Hill-Rom and Smith & Nephew, according to Kalorama. Other key players in the market include 3M, MoInlycke, B. Braun/Aesculap, ConvaTec, Baxter International and Hartmann.